Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-018-29923-4.pdf
Reference46 articles.
1. Hehlmann, R., Hochhaus, A. & Baccarani, M. & European, L. Chronic myeloid leukaemia. Lancet 370, 342–350, https://doi.org/10.1016/S0140-6736(07)61165-9 (2007).
2. Gambacorti-Passerini, C. et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103, 553–561, https://doi.org/10.1093/jnci/djr060 (2011).
3. Rosti, G., Castagnetti, F., Gugliotta, G. & Baccarani, M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol, https://doi.org/10.1038/nrclinonc.2016.139 (2016).
4. Kalmanti, L. et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29, 1123–1132, https://doi.org/10.1038/leu.2015.36 (2015).
5. Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872–884, https://doi.org/10.1182/blood-2013-05-501569 (2013).
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia;International Journal of Molecular Sciences;2024-03-14
2. Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia;Scientific Reports;2023-10-24
3. Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis;Leukemia;2023-10-17
4. Data integration between clinical research and patient care: A framework for context-depending data sharing and in silico predictions;PLOS Digital Health;2023-05-15
5. Gene Expression Pattern of ESPL1, PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML;Cancers;2023-05-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3